Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONE-D BPD: TMS + D-cycloserine in Suicidal Patients With Borderline Personality Disorder
NCT07460947Phase 2Recruiting
- Sponsor
- McLean Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of d-cycloserine in borderline personality disorder (BPD), sponsored by McLean Hospital. Started Jun 2026; status: recruiting.
02
Drugs
d-cycloserine
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT07460947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460947.